Home
Finance & valuation

Finance & valuation

SVB’s collapse is a reminder of how far IP finance still has to travel

Like many others, the bank held thousands of patents as security for loan deals, but almost certainly had no idea of their value – or lack of it

The Market Makers of 2022: top 20 revealed

Marconi's Kasim Alfalahi takes the top spot for Avanci's stellar showing in our countdown of the patent market’s most innovative and influential dealmakers and decision takers

Patent litigation finance skyrockets in past three years

We compiled data from Westfleet Advisors’ annual litigation funding reports to find patent finance shot up by nearly 50% since 2020 – to the benefit of rights holders

Latest content

Nokia Technologies boosts revenues and profits in strong Q3 patent licensing performance

Royalties grow on the back of new deals and renewals; company also shares new details on legal fight with Oppo, which does not appear to have significantly dimmed income outlook

29 October 2021

Hub and spoke IP strategies are generating billions of dollars in biopharma

New Crinetics spin-off is more evidence of the growing influence of models designed to monetise non-core life sciences assets

22 October 2021

Investment in medical device IP is surging

Diagnostic innovation buyouts drive resurgence of med-tech deal-making

19 October 2021

Ericsson turns in strong licensing quarter with Apple renewal looming

Continued impact of Samsung deal pushes Swedish company’s royalty take near $300 million – but executives warn upcoming re-negotiations could produce temporary disruption again

19 October 2021

Former Nortel and BlackBerry patents land with smartphone maker Honor

Transaction marks first outside patent acquisition since company was spun out from Huawei last year

13 October 2021

IPBC Europe in Dublin brought patent value issues to the fore

Saturday Opinion: A memorable two days in the Irish capital showed definitively that face-to-face trumps video and allowed for some detailed debate on key topics

09 October 2021

Four IP takeaways from Merck’s $11.5 billion Acceleron acquisition

Merck has struck the biggest life sciences M&A deal of 2021 so far. Here are the four key IP-related takeaways.

07 October 2021

Amgen’s Otezla win vindicates multi-billion-dollar IP purchase

US federal court victory sets up the $13.4 billion drug for exclusivity until 2028

05 October 2021

Purchase of Alphabet rights marks rare patent acquisition for Japan’s Softbank

Assignment records show that despite parent company’s vast backing for startups, Softbank Corp and its affiliates have not often come into the possession of significant third-party portfolios

04 October 2021

What patent owners need to know about financing life sciences disputes

The Long Read: Companies in the life sciences sector have increasing options when seeking outside investment in IP enforcement campaigns, writes Michael Gulliford. But unique legal considerations and risk factors call for careful structuring of deals

29 September 2021

Unlock unlimited access to all IAM content